Continuous Bioprocessing for Bispecific Antibodies: Innovations Accelerating Therapeutic Antibody Production (2024–2025)
Bispecific antibodies (BsAbs) are a transformative class of biologic drugs engineered to simultaneously bind two different targets, enhancing therapeutic effects and specificity, particularly in oncology and immunotherapy124.
As of 2025, the global bispecific antibody market is expanding rapidly, projected to grow from $12B in 2024 to $50B by 2030, underscoring intense industry demand for scalable and efficient manufacturing solutions23.
Continuous and high-throughput bioprocessing is increasingly leveraged to meet the need for rapid, scalable production of bispecifics, with leading providers able to deliver high-quality bispecific antibodies in as little as 2–3 weeks from gene synthesis to final product, enabling accelerated preclinical and clinical timelines2.
Recent technological advances—such as automated mammalian cell expression platforms, enhanced protein purification protocols (including high-capacity, alkaline-resistant Protein L resins), and rigorous quality control—have dramatically improved the scalability, speed, and reproducibility of bispecific antibody manufacturing24.
Modern production platforms support diverse bispecific antibody formats (including IgG-like, BiTE, DVD-Ig, and others) and use customizable workflows that accommodate various research and therapeutic demands2.
Process innovations are enabling higher binding specificity and lower risk of immunogenicity or off-target toxicities in BsAbs, critical for clinical translation and regulatory approval14.
Ongoing industry partnerships (e.g., BioNTech and Bristol Myers Squibb co-developing BNT327) and late-stage clinical trials highlight the continued investment in bispecifics and the need for robust, scalable bioprocess technologies to support commercial and clinical launches3.
Sources:
1. https://pmc.ncbi.nlm.nih.gov/articles/PMC12320366/
2. https://www.fiercebiotech.com/sponsored/speed-scale-and-success-rise-bispecific-antibodies-targeted-therapies
3. https://www.prnewswire.com/news-releases/bispecific-antibodies-in-oncology-market-forecast-to-surge-over-the-next-decade--delveinsight-302554858.html